Opinion|Videos|February 18, 2025
The Evolving Landscape: CAR T and Future Therapies in Early-Stage R/R Myeloma
Panelists discuss the key toxicities influencing chimeric antigen receptor (CAR) T-cell therapy selection for early relapsed/refractory multiple myeloma (R/R MM), the transition to community care post treatment, strategies for managing toxicities, the future of CAR T in early R/R MM, and the impact of emerging data on treatment sequencing, along with insights from the DREAMM-7 and DREAMM-8 studies and improving the CAR T process in academic and community settings.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In your opinion, what does the future look like for CAR T in early R/R MM?
- How does emerging data impact your approach to treatment sequencing in early R/R MM?
- DREAMM-7, belantamab mafodotin plusVd in R/R MM after 1 prior LOT
- DREAMM- 8, Belantamab mafodotin plus Pd in R/R MM after 1 prior LOT
- What clinical pearls can you share on how the overall CAR T process can improve in both the academic and community setting?
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA received a BLA for etentamig in relapsed/refractory multiple myeloma, based on response and PFS gains in the phase 3 CERVINO trial.
Elranatamab improved PFS vs 3 standard regimens in relapsed/refractory multiple myeloma in the phase 3 MagnetisMM-32 trial.
The FDA approved dostarlimab in rectal cancer and pembrolizumab in tumors with high mutational burden, Europe cleared teclistamab in myeloma, and more.
Advertisement
Advertisement
Trending on OncLive
1
RELATIVITY-1093 Trial Aims to Advance Nivolumab Plus Relatlimab and Chemo in Nonsquamous NSCLC
2
Dostarlimab Monotherapy Elicits Durable cCRs in dMMR/MSI-H Locally Advanced Rectal Cancer
3
NEXERA-303 Trial Aims to Bring TGFβR2×PD-1 Bispecific Antibody INCA33890 Into First-Line MSS CRC
4
The OncFive: Top Oncology Articles for the Week of 10/25
5